sodium benzoyl((4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazole-1-yl)phenyl)sulfonyl)amide | 1334394-60-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: sodium benzoyl((4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazole-1-yl)phenyl)sulfonyl)amide
• 英文别名: sodium benzoyl ((4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)sulfonyl)amide；sodium N-(4-(5-p-tolyl-3-(trifluoromethyl)-1-H-pyrazol-1-yl)phenylsulfonyl)benzamide；Sodium;benzoyl-[4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]sulfonylazanide；sodium;benzoyl-[4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]sulfonylazanide
• CAS: 1334394-60-3
• 化学式: C₂₄H₁₇F₃N₃O₃S*Na
• 分子量: 507.468
• InChiKey: VQVAOQIYIYYOJN-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  2.77
• 重原子数：
  35.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  83.13
• 氢给体数：
  0.0
• 氢受体数：
  5.0

反应信息

• 作为产物：
  描述：

  N-((4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)sulfonyl)benzamide 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 以61 %的产率得到sodium benzoyl((4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazole-1-yl)phenyl)sulfonyl)amide
  参考文献：
  名称：

  具有COX-2/5-LOX/TRPV1多功能抑制活性的N-(苯磺酰基)乙酰胺类抗炎镇痛药的合成及生物学评价

  摘要：

  本研究设计、合成了一系列结构新颖的N- (苯磺酰基)乙酰胺衍生物，并对其作为 COX-2/5-LOX/TRPV1 多靶点抑制剂进行了抗炎镇痛治疗的生物学评价。其中，9a和9b显示出良好的 COX-2（9a IC 50  = 0.011 μM，9b IC 50  = 0.023 μM），5-LOX（9a IC 50  = 0.046 μM，9b IC 50  = 0.31 μM）和 TRPV1（9a IC 50  = 0.008 μM，9b IC 50 = 0.14 μM) 抑制活性。在 SD 大鼠中以 10 mg/kg 剂量进行的9a药代动力学 (PK) 研究显示出高口服暴露、可接受的清除率和良好的生物利用度（Cmax = 5807.18 ± 2657.83 ng/mL，CL = 3.24 ± 1.47 mL/min /公斤，F = 96.8 %)。进一步的体内功效研究表明，9a能够改善福

  DOI：

  10.1016/j.bmcl.2022.129101

文献信息

• Chemical and in vitro enzymatic stability of newly synthesized celecoxib lipophilic and hydrophilic amides
  作者：Amjad M. Qandil、Farah H. El Mohtadi、Bassam M. Tashtoush

  DOI：10.1016/j.ijpharm.2011.06.013

  日期：2011.9

  Five celecoxib (CXB) acylamide sodium salts, MP-CXB, Cy-CXB, Bz-CXB, CBz-CXB and FBz-CXB were synthesized and characterized. Two simple, fast and validated RP-HPLC methods were developed for simultaneous quantitative determination of the amides and celecoxib in aqueous and biological samples and LOD and LOQ were <= 13.6 and <= 40 ng/mL, respectively. The solubility and logP(app) of the amides, in relevant media, were determined. The chemical hydrolysis, at 60,70 and 80 degrees C, of MP-CXB was studied at GIT-relevant pH (1.2, 6.8 and 7.4) and of CY-CXB was studied at skin relative pH (5.4 and 7.4). Significant hydrolysis was observed for MP-CXB at pH 1.2 only with half-lives 28.28, 11.64 and 3.53h at 60, 70 and 80 degrees C, respectively, with extrapolated half-lives of 2060 and 443 h at 25 and 37 degrees C, respectively. The hydrolysis of all amides was studied in rat live homogenate and only Cy-CXB was hydrolyzed with half-life of 3.79 h. The hydrolysis of MP-CXB and Cy-CXB was studied in human plasma and neither was hydrolyzed. It is finally suggested that hydrophobic interactions plays a role in the binding of susceptible acylamides to the hepatic hydrolyzing enzyme since only amides with saturated hydrocarbon chains underwent hydrolysis. (C) 2011 Elsevier B.V. All rights reserved.